The PICI Center at Weill Cornell Medicine performs discovery research to guide the development of new immunotherapeutic approaches that will be delivered by a diverse workforce to all populations. Recognizing the tremendous impact that immunotherapy can have in some cancers but also seeing the unmet clinical need in others, the PICI Center at WCM brings together basic scientists studying cancer cell biology with immunologists and T cell engineers to address these needs. This innovative, multi-disciplinary approach to deploying new therapies across a large, diverse catchment area is achieved through the collaboration of scientists and physician-scientists, community outreach professionals, veterinary oncologists and biomedical engineers. Jedd Wolchok, MD, PhD | Director Taha Merghoub, PhD | Co-Director All Investigators Related Point of View Guest Post: PICI Catalyzes Scientific Innovation Clinical Trial The AMADEUS Trial Clinical Trial The McGRAW Trial Clinical Trial The PRINCE Trial Announcement PICI 2024: Collaborative Breakthroughs in Cancer Immunotherapy Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024 Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research
Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy
Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn